- Home
- NVOS vs VCNX Comparison
NVOS vs VCNX Comparison
Compare NVOS & VCNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVOS
- VCNX
- Stock Information
- Founded
- NVOS 2000
- VCNX 2001
- Country
- NVOS United States
- VCNX United States
- Employees
- NVOS N/A
- VCNX N/A
- Industry
- NVOS Assisted Living Services
- VCNX Biotechnology: Pharmaceutical Preparations
- Sector
- NVOS Health Care
- VCNX Health Care
- Exchange
- NVOS Nasdaq
- VCNX Nasdaq
- Market Cap
- NVOS 7.4M
- VCNX 9.4M
- IPO Year
- NVOS 2017
- VCNX N/A
- Fundamental
- Price
- NVOS $0.28
- VCNX $5.63
- Analyst Decision
- NVOS
- VCNX
- Analyst Count
- NVOS 0
- VCNX 0
- Target Price
- NVOS N/A
- VCNX N/A
- AVG Volume (30 Days)
- NVOS 489.3K
- VCNX 27.5K
- Earning Date
- NVOS 07-19-2024
- VCNX 08-14-2024
- Dividend Yield
- NVOS N/A
- VCNX N/A
- EPS Growth
- NVOS N/A
- VCNX N/A
- EPS
- NVOS N/A
- VCNX N/A
- Revenue
- NVOS $13,516,958.00
- VCNX $356,000.00
- Revenue This Year
- NVOS N/A
- VCNX N/A
- Revenue Next Year
- NVOS N/A
- VCNX N/A
- P/E Ratio
- NVOS N/A
- VCNX N/A
- Revenue Growth
- NVOS 1102.98
- VCNX N/A
- 52 Week Low
- NVOS $0.27
- VCNX $4.21
- 52 Week High
- NVOS $5.38
- VCNX $52.50
- Technical
- Relative Strength Index (RSI)
- NVOS 24.63
- VCNX 52.30
- Support Level
- NVOS $0.29
- VCNX $5.07
- Resistance Level
- NVOS $0.41
- VCNX $5.85
- Average True Range (ATR)
- NVOS 0.04
- VCNX 0.34
- MACD
- NVOS -0.00
- VCNX 0.09
- Stochastic Oscillator
- NVOS 9.25
- VCNX 76.84
About NVOS Novo Integrated Sciences Inc.
Novo Integrated Sciences Inc is a medical care company. It provides specialized physiotherapy, chiropractic care, occupational therapy, eldercare, laser therapeutics, massage therapy, acupuncture, neurological functions, kinesiology, and others. It has two reportable segments: healthcare services which generates majority of the revenue, and product sales.
About VCNX Vaccinex Inc.
Vaccinex Inc is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The company's lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. The firm has also developed a proprietary drug discovery platform, ActivMAb.